OTCMKTS:AMAR Amarillo Biosciences (AMAR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Amarillo Biosciences Stock (OTCMKTS:AMAR) Get Amarillo Biosciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume6,100 shsAverage Volume18,253 shsMarket Capitalization$25.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Amarillo Biosciences, Inc. is a biotechnology company focused on developing orally administered interferon-based therapies. Its research has centered on low-dose oral interferon alpha, an approach intended to stimulate the body’s immune response without the administration methods commonly associated with injectable interferon treatments. The company has investigated oral interferon alpha for potential applications in human and veterinary medicine, including respiratory infections and other conditions involving immune-system regulation. Amarillo Biosciences has also pursued licensing, research, and development collaborations to support the evaluation and commercialization of its technology in selected markets. Based in Amarillo, Texas, the company has historically operated as a development-stage biotechnology business. Publicly available information about its current product portfolio, commercial operations, geographic reach, and leadership is limited, and its activities have primarily been associated with the research and development of interferon-based therapies.AI Generated. May Contain Errors. Read More Receive AMAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarillo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMAR Stock News HeadlinesAmarillo native earns Rising Star awardJune 26, 2025 | msn.comAmarillo native, Navy veteran earns Rising Star Award for leadership in electric vehicle sectorJune 26, 2025 | msn.comUrgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20thMarc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a system that flagged Nvidia before it climbed more than 50,000%. Following Executive Order #14363, next-generation AI data centers are coming online, and Chaikin says one stock is leading this buildout.October 12 at 1:00 AM | Chaikin Analytics (Ad)Vikings Acquire RB Cam Akers in Midseason Trade With TexansOctober 17, 2024 | msn.comFrance’s divided National Assembly votes to keep centrist speaker as political turmoil persistsJuly 20, 2024 | msn.comAmarillo, United States - Weather Forecasts | Maps | News - Yahoo WeatherMay 7, 2024 | yahoo.comOvernight shooting incidents in Amarillo leave 1 dead, 1 critically injuredJanuary 26, 2024 | yahoo.comGufic Biosciences Ltd (GUFI)December 20, 2023 | investing.comSee More Headlines AMAR Stock Analysis - Frequently Asked Questions How were Amarillo Biosciences' earnings last quarter? Amarillo Biosciences, Inc. (OTCMKTS:AMAR) issued its quarterly earnings results on Wednesday, November, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm earned $0.02 million during the quarter. What other stocks do shareholders of Amarillo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amarillo Biosciences investors own include Fulcrum Therapeutics (FULC), Cerecor (CERC), AquaBounty Technologies (AQB), Astria Therapeutics (ATXS) and Company Calendar Last Earnings11/14/2018Today10/12/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorTechnology Industry Technology Hardware, Storage & Peripherals Sub-IndustryTechnology Hardware, Storage & Peripherals Current SymbolOTCMKTS:AMAR CIK1014763 Webwww.amarbio.com Phone806-376-1741FaxN/AEmployees2Year Founded1984Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.45 million Net Margins-41,453.98% Pretax MarginN/A Return on EquityN/A Return on Assets-574.29% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.07 Sales & Book Value Annual Sales$20 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / BookN/AMiscellaneous Outstanding Shares42,066,000Free FloatN/AMarket Cap$25.24 million OptionableNot Optionable Beta-0.06 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:AMAR) was last updated on 5/21/2021 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredUrgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20thMarc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...Chaikin Analytics | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | SponsoredTrump To Relaunch USD?President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe AI Infrastructure Play Kevin O'Leary Is BackingKevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...The Tomorrow Investor | SponsoredFox News: Wall Street Can Seize Your RetirementFox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarillo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarillo Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
